The question should be whether the timing of vaccination optimises the impact on child health

Fisker, Ane Bærent

Published in:
B M J

DOI:
10.1136/bmj.i1713

Publication date:
2016

Document version
Publisher's PDF, also known as Version of record

Document license
CC BY-NC

Citation for published version (APA):
Fisker, A. B. (2016). The question should be whether the timing of vaccination optimises the impact on child health. B M J, 352, [i1713]. https://doi.org/10.1136/bmj.i1713

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
The question should be whether the timing of vaccination optimises the impact on child health

Ane B Fisker postdoctoral researcher
Research Center for Vitamins and Vaccines (CVIVA), Bandim Health Project, Statens Serum Institut, Denmark, and Bandim Health Project, Guinea-Bissau

Rather than asking whether there is evidence that the timing of the vaccination programme prevents the targeted diseases, the question should be whether the timing optimises the impact on child health. That evidence base is insufficient. In low income countries, where the burden of child mortality lies, the vaccines at the core of the Expanded Programme on Immunization were not evaluated for their effect on mortality before being introduced. The four core vaccines—BCG, the diphtheria-tetanus-pertussis vaccine (DTP), the oral polio vaccine (OPV), and the measles vaccine (MV)—all have non-specific effects on child health beyond specific disease protection. These non-specific effects are strongest when the vaccine is the most recent. They have not been taken into account in the current timing of the vaccines. NSEs have mainly been demonstrated in observational studies. However, randomised trials have supported the conclusions by showing that the live attenuated vaccines—BCG, OPV, and MV—reduce mortality more than predicted by the prevention of the target infections. By contrast, DTP is associated with increased female mortality. Both the “yes” and “no” side state that the time for randomised trials has passed, as it is not ethical to deprive children of a vaccine that is part of the recommended schedule. The Strategic Advisory Group of Experts on Immunization (SAGE) recently reviewed the evidence for the non-specific effects of BCG, DTP, and MV on all cause child mortality and recommended further research and where possible randomised trials. With the limited evidence behind the current timing, and an increasing amount of evidence documenting that changes to the current schedule may improve child health, there should be equipoise for studies evaluating alternative schedules.

Competing interests: None declared.

The work on the non-specific effects of vaccines was supported by the Danish Council of Independent Research (DFF-1333-00192), European Union FP7 support for OPTIMUMISE (Health F3-2011-261375), and the Danish National Research Foundation (DNRF108).

Full response at: http://www.bmj.com/content/352/bmj.i867/rr-9.


Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions

a.fisker@bandim.org

For personal use only: See rights and reprints http://www.bmj.com/permissions
Subscribe: http://www.bmj.com/subscribe